Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist

  title={Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist},
  author={Tomoyasu Tsushima and Yasutomo Nasu and Takashi Saika and Yoshio Maki and Masatoshi Noda and Bunzo Suyama and Toyoko Yamato and Hiromi Kumon},
  journal={Urologia Internationalis},
  pages={135 - 139}
Objective: Flare-up phenomena, such as an increase in prostate-specific antigen (PSA) and/or deterioration of symptoms, are observed in some patients undergoing gonadotropin-releasing hormone (GnRH) agonist therapy. This study was carried out to determine the optimal time for starting the administration of flutamide to prevent flare-up phenomena. Patients and Methods: Twenty-six patients with prostate cancer and elevated serum levels of PSA were randomly assigned to 5 groups. Group A patients… 

Figures and Tables from this paper

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
Although there is no FDA indication for BIC use as monotherapy, 44% of patients in this study used BIC alone or as part of CAB followed by monotherapy; further research is necessary to understand the outcomes of BIC utilization in these settings, particularly compared with newer second-generation anti-androgens.
Degarelix in the Treatment of Prostate Cancer
Degarelix was found to have no initial testosterone surge, reach castrate levels of testosterone by day three, have no testosterone microsurges, have the ability to keep follicle stimulating hormone suppressed and have lower histaminogenic potency compared to its predecessor abarelix.
Discovery of a pituitary adenoma following a gonadotropin‐releasing hormone agonist in a patient with prostate cancer
It is advocated that a high index of suspicion of pituitary tumor must be considered in any case of intracranial hypertension following the administration of GnRH agonist, and Abarelix could have a place in such cases.
Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer
The fact that with the onset of castration-resistance in late stage metastatic disease, a prolongation of ADT in combination with a second line hormonal manipulation is recommended supports the importance of the compound for daily clinical practice.
Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
GnRH receptor antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer are reviewed.


Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
It is concluded that nilutamide can prevent the adverse consequences of the buserelin-induced transient rise in plasma testosterone levels in men with advanced prostate cancer treated with a GnRH analogue.
[Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
To eliminate the initial testosterone (T) surge and prevent the risk of flare-up induced by the first administration of luteinizing hormone-releasing hormone (LH-RH) analogue, we examined the
Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Pretreatment with CPA allows a safer use of LH-RH analogs in the treatment of metastatic carcinoma of the prostate, and blunted the initial rise of testosterone which never rose above pretreatment levels.
Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy.
The usefulness of estramustine phosphate for preventing flare-up in goserelin acetate depot therapy for advanced prostate cancer was studied and its effect was considered to be more marked than that of short-term treatment with antiandrogens.
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Goserelin seems to be preferred to surgery by the majority of patients given a choice of treatment, and importantly in a palliative care situation where there are no survival advantages for treatment alternatives, it appears to have a more beneficial effect on the quality of life than surgery.
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
Small noncomparative trials reveal that leuprorelin also causes regression of benign hyperplastic prostate tissue with corresponding relief of obstructive, but not irritative, symptoms although continuous treatment is necessary to maintain remission.